GLP-1 Receptor Agonists and Dermatologic Outcomes in Type 2 Diabetes
Key Takeaways
- Compared with DPP-4 inhibitor initiation, GLP-1 receptor agonist initiation was associated with higher psoriasis risk and lower pemphigus and bullous pemphigoid risk.
- Other inflammatory or autoimmune skin outcomes were not significantly different after multiple-testing correction.
- The analysis emulated an active-comparator trial in matched adults with type 2 diabetes, followed patients for up to 4 years, and showed similar results in subgroup and sensitivity analyses.
The analysis used the TriNetX US Collaborative Network in a large real-world active-comparator target trial emulation. Adults with type 2 diabetes who started GLP-1 receptor agonists or DPP-4 inhibitors between January 1, 2018, and December 31, 2022, were eligible. Investigators excluded prior users of either class and used 1:1 propensity score matching to create balanced cohorts of 169,630 patients in each group. Outcomes within 3 months after treatment initiation were set aside to reduce protopathic bias, and follow-up continued for as long as 4 years. Cox regression generated hazard ratios with 95% confidence intervals, and the comparison remained a matched observational emulation rather than a randomized trial.
In the matched analysis, outcome estimates separated into one increased association and two decreased associations among the highlighted dermatologic conditions. Investigators found a higher risk of incident psoriasis with GLP-1 receptor agonist initiation, HR 1.19 (95% CI 1.11-1.28). They also observed lower risks of pemphigus, HR 0.32 (95% CI 0.16-0.63), and bullous pemphigoid, HR 0.61 (95% CI 0.43-0.87). Other inflammatory or autoimmune skin outcomes did not differ significantly after multiple-testing correction across the remaining reported categories. These differences appeared confined to selected conditions rather than spread across the broader dermatologic outcome set.
The associations persisted across subgroup and sensitivity analyses, showing consistency across the analytic checks described in the abstract. The concluding language placed the findings within the dermatologic safety profile surrounding incretin therapy and noted the relevance of ongoing skin monitoring.
Frequently Asked Questions
What are the dermatologic side effects of GLP-1 receptor agonists in patients with type 2 diabetes?
In a large real-world active-comparator target trial emulation using the TriNetX US Collaborative Network (1:1 propensity-matched cohorts of 169,630 adults with type 2 diabetes; index 2018-2022; up to 4-year follow-up; 3-month washout to reduce protopathic bias), GLP-1 receptor agonist initiation was associated with a roughly 19% higher hazard of incident psoriasis versus DPP-4 inhibitors (HR 1.19; 95% CI 1.11-1.28), a lower hazard of pemphigus (HR 0.32; 95% CI 0.16-0.63), and a lower hazard of bullous pemphigoid (HR 0.61; 95% CI 0.43-0.87). Other inflammatory or autoimmune skin outcomes did not differ significantly after multiple-testing correction. The associations persisted across subgroup and sensitivity analyses.
What are the latest treatment options for type 2 diabetes — and how should dermatologic monitoring fit in?
Current T2D treatment commonly includes basal insulin layered with SGLT2 inhibitors, GLP-1 receptor agonists, and dual GIP/GLP-1 receptor agonists (tirzepatide); DPP-4 inhibitors remain in use as an alternative or earlier-line option. The dermatologic-outcomes signal in this Frontiers in Endocrinology analysis — higher psoriasis but lower pemphigus and bullous pemphigoid risk with GLP-1 RAs versus DPP-4i — supports adding dermatologic history to the GLP-1 RA initiation workup and counseling patients to report new or worsening skin findings. ReachMD's Advances in Obesity Management Learning Center and Endocrinology CME aggregate accredited education on the broader T2D pharmacotherapy landscape, including class-level side-effect profiles.
Which patients with T2D should clinicians watch most closely for incident psoriasis after starting a GLP-1 RA?
The analysis was at class level and did not stratify the headline psoriasis signal by drug, dose, or specific T2D phenotype. Reasonable surveillance candidates based on broader dermatologic risk literature include T2D patients with a personal or family history of psoriasis, baseline psoriatic plaques, obesity, metabolic syndrome features, or smoking. Counseling at initiation should set expectations that new pruritic or plaque-like lesions warrant dermatology referral. Conversely, the lower pemphigus and bullous pemphigoid signals suggest that in T2D patients already at higher risk for autoimmune blistering disease (e.g., older adults on DPP-4 inhibitors with concerning skin findings), choosing or switching to a GLP-1 RA does not appear to add — and may modestly reduce — that specific risk.
What are the design limits and biases of this analysis?
This is an observational target trial emulation, not a randomized trial. Despite 1:1 propensity score matching on measured sociodemographic and clinical factors, residual confounding by unmeasured variables (lifestyle, indication preference, prior dermatology history not coded in TriNetX) remains possible. The 3-month washout after treatment initiation reduces protopathic bias but does not eliminate it. Outcome ascertainment depends on coded diagnoses in the TriNetX network. The class-level analysis does not distinguish between specific GLP-1 RAs, doses, or duration of therapy. Subgroup and sensitivity analyses were consistent with the primary findings, which adds confidence within the limits of the design.
How does this fit with the SCALE 2026 dermatologic findings and broader cluster evidence?
The SCALE 2026 presentations (Keaney; Ablon) focused on aesthetic and procedural consequences in primarily non-diabetic obesity populations (facial volume loss, telogen effluvium, muscle loss, immune-mediated reactions including rare bullous pemphigoid). This study complements those presentations by quantifying, in a large T2D cohort, the directional risk of selected autoimmune and inflammatory skin outcomes versus an active comparator (DPP-4 inhibitors). Together they support a unified clinical posture: dermatologic history at GLP-1 RA initiation, patient counseling about new skin findings, and low-threshold dermatology referral for psoriasis flares or blistering reactions.